text:
Revision and update on clinical practice guideline for liver cirrhosis.
- Ki Tae Suk
- Soon Koo Baik
- Jung Hwan Yoon
- Jae Youn Cheong
- Yong Han Paik
- Chang Hyeong Lee
- Young Seok Kim
- Jin Woo Lee
- Dong Joon Kim
- Sung Won Cho
- Seong Gyu Hwang
- Joo Hyun Sohn
- Moon Young Kim
- Young Bae Kim
- Jae Geun Kim
- Yong Kyun Cho
- Moon Seok Choi
- Hyung Joon Kim
- Hyun Woong Lee
- Seung Up Kim
- Ja Kyung Kim
- Jin Young Choi
- Dae Won Jun
- Won Young Tak
- Byung Seok Lee
- Byoung Kuk Jang
- Woo Jin Chung
- Hong Soo Kim
- Jae Young Jang
- Soung Won Jeong
- Sang Gyune Kim
- Oh Sang Kwon
- Young Kul Jung
- Won Hyeok Choe
- June Sung Lee
- In Hee Kim
- Jae Jun Shim
- Gab Jin Cheon
- Si Hyun Bae
- Yeon Seok Seo
- Dae Hee Choi
- Se Jin Jang
- Hyo Jung Cho, Soon Sun Kim, Seun Joo Ahn, Joo Han Park, Dong Joon Kim, Young Bae Kim, Sung Won Cho, Jae Youn Cheong[Show abstract] [Hide abstract]
ABSTRACT: Transferrin and alpha-1 antitrypsin are reportedly associated with liver fibrosis. We evaluated the usefulness of serum transferrin and alpha-1 antitrypsin as new liver fibrosis markers in patients with chronic hepatitis B. The study included 293 patients with chronic hepatitis B who underwent a liver biopsy between October 2005 and June 2009, and who had no history of hepatocellular carcinoma. Serum markers and liver fibrosis stages were compared. Univariate analysis revealed that age (P<0.001), serum platelet count (P<0.001), and serum alkaline phosphatase level (P=0.003) differed significantly between the patients with and without liver cirrhosis. Serum transferrin levels were significantly lower in advanced fibrosis than in mild fibrosis in both univariate analysis (P=0.002) and multivariate analysis (P=0.009). In addition, the serum transferrin level was significantly lower in cirrhotic patients than in noncirrhotic patients (P=0.020). However, the serum level of alpha-1 antitrypsin was not significantly associated with liver cirrhosis in patients with chronic hepatitis B. Serum transferrin could be promising serum marker for predicting advanced liver fibrosis in patients with chronic hepatitis B.Clinical and molecular hepatology. 12/2014; 20(4):347-54. -
Article: Alcoholic liver disease: Treatment.
[Show abstract] [Hide abstract]
ABSTRACT: The excess consumption of alcohol is associated with alcoholic liver diseases (ALD). ALD is a major healthcare problem, personal and social burden, and significant reason for economic loss worldwide. The ALD spectrum includes alcoholic fatty liver, alcoholic hepatitis, cirrhosis, and the development of hepatocellular carcinoma. The diagnosis of ALD is based on a combination of clinical features, including a history of significant alcohol intake, evidence of liver disease, and laboratory findings. Abstinence is the most important treatment for ALD and the treatment plan varies according to the stage of the disease. Various treatments including abstinence, nutritional therapy, pharmacological therapy, psychotherapy, and surgery are currently available. For severe alcoholic hepatitis, corticosteroid or pentoxifylline are recommended based on the guidelines. In addition, new therapeutic targets are being under investigation.World journal of gastroenterology : WJG. 09/2014; 20(36):12934-12944. -
Article: Clinical Features of Non-alcoholic Fatty Liver Disease in Cryptogenic Hepatocellular Carcinoma
Min Young Rim, Oh Sang Kwon, Minsu Ha, Ju Seung Kim, Kwang Il Ko, Dong Kyu Kim, Pil Kyu Jang, Jung Yoon Han, Pyung Hwa Park, Young Kul Jung, Duck Joo Choi, Yun Soo Kim, Ju Hyun Kim[Show abstract] [Hide abstract]
ABSTRACT: Nonalcoholic fatty liver disease (NAFLD) may be one of the important causes of cryptogenic hepatocellular carcinoma (HCC). The aim of this study was to evaluate whether patients with cryptogenic HCC share clinical features similar to that of NAFLD.The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi 05/2014; 63(5):292-8.
Page 1
The Korean Journal of Hepatology 2012;18:1-21
pISSN: 1738-222X eISSN: 2093-8047
Revision and update on clinical practice guideline
for liver cirrhosis
Ki Tae Suk1, Soon Koo Baik2*, Jung Hwan Yoon3*, Jae Youn Cheong4, Yong Han Paik5,
Chang Hyeong Lee6, Young Seok Kim7, Jin Woo Lee8, Dong Joon Kim1, Sung Won Cho4,
Seong Gyu Hwang9, Joo Hyun Sohn10, Moon Young Kim2, Young Bae Kim11, Jae Geun Kim12,
Yong Kyun Cho5, Moon Seok Choi5, Hyung Joon Kim13, Hyun Woong Lee13, Seung Up Kim14,
Ja Kyung Kim14, Jin Young Choi15, Dae Won Jun16, Won Young Tak17, Byung Seok Lee18,
Byoung Kuk Jang19, Woo Jin Chung19, Hong Soo Kim20, Jae Young Jang21, Soung Won Jeong21,
Sang Gyune Kim7, Oh Sang Kwon22, Young Kul Jung22, Won Hyeok Choe23, June Sung Lee24,
In Hee Kim25, Jae Jun Shim26, Gab Jin Cheon27, Si Hyun Bae28, Yeon Seok Seo29,
Dae Hee Choi30, and Se Jin Jang31 (random order)
1Department of Internal Medicine, Hallym University College of Medicine, Chuncheon; 2Department of Internal
Medicine and Cell Therapy and Tissue Engineering Center, Yonsei University Wonju College of Medicine, Wonju;
3Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine,
Seoul; 4Department of Internal Medicine, Ajou University College of Medicine, Suwon; 5Department of Internal
Medicine, Sungkyunkwan University College of Medicine, Seoul; 6Department of Internal Medicine, Catholic
University of Daegu College of Medicine, Daegu; 7Department of Internal Medicine, Soonchunhyang University
Hospital Bucheon, Soonchunhyang University College of Medicine, Bucheon; 8Department of Internal Medicine,
Inha University College of Medicine, Incheon; 9Department of Internal Medicine, Cha University College of
Medicine, Seongnam; 10Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University
College of Medicine, Guri; Departments of 11Pathology and 12Radiology, Ajou University College of Medicine,
Suwon; 13Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul; Departments of
14Internal Medicine and 15Radiology, Yonsei University College of Medicine, Seoul; 16Department of Internal
Medicine, Hanyang University Seoul Hospital, Hanyang University College of Medicine, Seoul; 17Department of
Internal Medicine, Kyungpook National University College of Medicine, Daegu; 18Department of Internal Medicine,
Chungnam National University College of Medicine, Daejeon; 19Department of Internal Medicine, Keimyung
University College of Medicine, Daegu; 20Department of Internal Medicine, Soonchunhyang University Hospital
Cheonan, Soonchunhyang University College of Medicine, Cheonan; 21Department of Internal Medicine,
Soonchunhyang University Hospital Seoul, Soonchunhyang University College of Medicine, Seoul; 22Department of
Internal Medicine, Gachon University of Medicine and Science, Incheon; 23Department of Internal Medicine,
Konkuk University College of Medicine, Seoul; 24Department of Internal Medicine, Inje University College of
Medicine, Goyang; 25Department of Internal Medicine, Chonbuk National University College of Medicine, Jeonju;
26Department of Internal Medicine, Kyung Hee University College of Medicine, Seoul; 27Department of Internal
Medicine, Ulsan University College of Medicine, Gangneung; 28Department of Internal Medicine, The Catholic
University of Korea College of Medicine, Seoul; 29Department of Internal Medicine, Korea University College of
Medicine, Seoul; 30Department of Internal Medicine, Kangwon National University College of Medicine,
Chuncheon; 31Department of Preventive Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea
Keywords: Liver cirrhosis; Clinical practice guideline
Received February 12, 2012; Accepted March 5, 2012
Abbreviations: CHB, chronic hepatitis B; CHC, chronic hepatitis C; EVL, endoscopic variceal ligation; EVO, endoscopic variceal obturation; GOV,
gastroesophageal varices; IGV, isolated gastric varices; LC, liver cirrhosis; LOLA, L-ornithine-L-aspartate; PMN, polymorphonuclear leukocyte;
SBP, spontaneous bacterial peritonitis; TIPS, transjugular intrahepatic portosystemic shunt
*Co-corresponding author:
Soon Koo Baik
Division of Gastroenterology & Hepatology, Department of Internal Medicine and Cell Therapy and Tissue Engineering Center, Yonsei University
Wonju College of Medicine, 162 Ilsan-ro, Wonju 220-701, Korea
Tel. +82-33-741-1229, Fax. +82-33-741-1228, E-mail; email@example.com
Jung Hwan Yoon
Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu,
Seoul 110-744, Korea
Tel. +82-2-2072-2731, Fax. +82-2-743-6701, E-mail; email@example.com
Copyright Ⓒ 2012 by The Korean Association for the Study of the Liver
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Page 2
2 The Korean Journal of Hepatology Vol. 18. No. 1, March 2012
Table 1. Grading evidence and recommendations
High qualityFurther research is very unlikely to change our confidence in the estimate of effectA
Moderate quality Further research is likely to have an important impact on our confidence in the estimate of effect and
may change the estimate
Low qualityFurther research is very likely to have an important impact on our confidence in the estimate of effect
and is likely to change the estimate. Any change of estimate is uncertain
Strong Factors influencing the strength of the recommendation included the quality of the evidence, presumed
patient-important outcomes, and cost
Weak Variability in preferences and values, or more uncertainty. Recommendation is made with less
certainty, higher cost or resource consumption
Liver cirrhosis (LC) is a disease with a high rate of
prevalence and one of the most common causes of mortality
in the Republic of Korea (hereafter "Korea"). In Korea,
the main etiologies of LC have been found to be chronic
hepatitis B (CHB), alcohol, and chronic hepatitis C (CHC).
In patients with complications such as ascites, variceal
bleeding, and encephalopathy, the 5-year survival rates were
32%, 21%, and 40%, respectively, reflecting the poor
prognosis of patients with LC. Consequently, a clinical practice
guideline appropriate for the medical milieu of Korea is
important for both patients and clinicians.
In 2005, the Korean Association for the Study of the Liver
established a guideline for the treatment of LC that is now
widely used. However, it is currently necessary to revise and
update the clinical practice guideline based on new evidence
over the past 6 years regarding the diagnosis, treatment, and
prevention of LC. Therefore, the Korean Association for the
Study of the Liver undertook a revision and update of
the clinical practice guideline co-organized by the Liver
Cirrhosis Clinical Research Center. This guideline was based
on an interdisciplinary (hepatology, radiology, pathology, and
preventive medicine) approach. A panel of experts selected
by the Korean Association for the Study of the Liver and
Liver Cirrhosis Clinical Research Center met several times
to discuss and write this guideline during 2005-2011. This
guideline was written in light of published studies retrieved
from MEDLINE, EMBASE, and Cochrane Library. The
panel aimed to address 5 subjects: diagnosis of LC, anti-
fibrotic therapy for LC, variceal bleeding, ascites, and hepatic
The evidence and recommendations made in this
guideline have been graded according to the GRADE
(Grading of Recommendations Assessment Development
and Evaluation) system. The strength of evidence has
been classified into 3 levels: A (high-quality evidence), B
(moderate-quality evidence), and C (low-quality evidence).
The strength of recommendation has been classified into 2
categories: strong and weak (Table 1). Where there was no
clear evidence, the recommendations were based on the
consensus expert opinion(s) in literature and that of the
writing committee.
1. Diagnosis of LC
LC is a pathologically defined disease, and is clinically
classified as compensated and decompensated LC. Decom-
pensated LC includes cases with ascites, variceal bleeding,
hepatic encephalopathy, or jaundice. Image studies for
diagnosing LC are CT, abdominal ultrasound, and MRI.
Typical findings of these images are nodular liver surface,
splenomegaly, and the presence of intra-abdominal collateral
vessels, which mean increasing portal venous pressure.
Although there are not established criteria for the diagnosis
of compensated LC, imaging studies may be helpful for the
diagnosis of LC b y integrating laboratory findings such as
albumin, bilirubin, or prothrombin time and platelet values.
1-1. Diagnostic approach-patient history, physical
examination, and laboratory tests
When dealing with patients with LC, evaluation of the
cause, severity, and stage is the first step. In patients with
chronic liver disease, history taking (drug use, blood transfusion,
or alcohol use), physical examination (jaundice, ascites,
Page 3
Ki Tae Suk, et al. Revision and update on clinical practice guideline for liver cirrhosis 3
1. What test is needed for the diagnosis of LC in patients with
chronic liver disease?
- Find evidence for LC by history taking and physical
examination. (A1)
- In patients with chronic liver disease, to find LC, the
following tests are recommended and the findings in
parentheses should be checked. (A1)
(1) Complete blood count with platelet count
(2) Liver function test (hypoalbuminemia)
(3) Prolonged prothrombin time
(4) Imaging studies (nodularity of liver surface and
findings of LC)
(5) Endoscopy (presence of varices)
- The cause of LC should be examined including hepatitis
B virus and hepatitis C virus tests. (A1)
- The severity of LC could be assessed by Child-Pugh
classification with score. (B1)
2. Which findings are compatible with the diagnosis of LC in
the imaging studies?
- For the diagnosis of LC, compatible findings of imaging
studies (abdominal ultrasound, CT, and MRI) are
morphologic changes (nodularity of liver surface, atrophy
of the right lobe, hypertrophy of the left and caudate lobe,
expansion of the periportal space, and intrahepatic
nodule), ascites, and presence of portal hypertension
(collateral vessel or splenomegaly). (B1)
spider angioma, hepatomegaly, or splenomegaly), and symptom
such as fatigue from hepatitis should be assessed. In patients
with LC, a whole blood test including platelet count, liver
function test (albumin, aspartate aminotransferase, alanine
aminotransferase, alkaline phosphatase, and gamma glutamyl
transpeptidase), prothrombin time, abdominal ultrasound,
abdominal CT, and endoscopy should be carried out to
confirm the presence or absence of cirrhosis. In addition,
laboratory tests for hepatitis B or C virus infection are
needed for the evaluation of its cause. Generally, the Child-
Pugh score is used to assess the severity of LC. In clinical
practice for the diagnosis of LC, findings of portal hyper-
tension such as ascites, hepatic encephalopathy, or varices,
imaging findings, and laboratory findings are common
diagnostic tools. Recently, it was found that nodularity of
the liver surface, a platelet count of less than 100,000/mm3,
albumin less than 3.5 g/dL, and an international normalized
ratio of 1.3 or more are related to the presence of LC.
Presence of one condition of these findings showed a
specificity of 90.42% and a sensitivity of 61.11%.1
1-2. Imaging modalities for the diagnosis of LC
Abdominal ultrasound is safe and less expensive, and it
can be easily used as a screening test for the diagnosis of LC.
Abdominal ultrasound confirms the size of the liver,
echogenicity of the liver parenchyme, morphological
changes of the liver, ascites, and thrombus of the portal vein.
Typical ultrasound finding of LC is a coarse echo pattern by
fibrosis and regeneration. This finding ranges from mild
coarsening to visible nodules. The accuracy of CT in
diagnosing LC is 66-95%.2-6 The most important CT finding
for the diagnosis of LC is nodularity caused by regenerative
nodules, fibrosis scars, and lobar non-uniform atrophy and
hypertrophy. Nodularity of the liver surface showed a
specificity of 95%.2-4,7 Additionally, other radiologic findings
such as splenomegaly, blunt angle, morphological changes
(nodularity of liver surface, atrophy of right lobe, hypertrophy
of left and caudate lobe, expansion of periportal space, and
intrahepatic nodule), velocity of portal flow, shape of
hepatic vein waveform (Doppler test),2,4,8 and caudate
lobe/right lobe ratio (CT or MRI) are useful indices.9 If the
caudate lobe/right lobe ratio is above 0.65, it can indicate
LC, and its sensitivity, specificity, and accuracy reach 84%,
100%, and 94%, respectively.10
1-3. Pathological diagnosis of liver cirrhosis
The gold standard for confirming the diagnosis of LC is
liver biopsy, but it is invasive and susceptible to a sampling
error and inter-observer discrepancy. Therefore, liver biopsy
has not been widely used in clinical practice. Liver biopsy
can be carried out selectively for evaluating activity of the
underlying disease and fibrosis. Particularly, when cirrhosis
is diagnosed by clinical findings and imaging studies, but
not compatible with laboratory data, a liver biopsy is
especially helpful for diagnosing LC.11
1-4. Others
The serum markers for liver fibrosis directly or indirectly
reflect extracellular matrix metabolism. However, their
clinical utility in the diagnosis of LC has not been verified.12
FibroScan has been introduced to measure liver elasticity
noninvasively and is an objective diagnostic tool for the
diagnosis of LC. However, there is no exact guideline on
how to apply it clinically, and there is some variation in its
diagnostic accuracy for the diagnosis of LC. Therefore, the
practical use of FibroScan is limited.
Page 4
4 The Korean Journal of Hepatology Vol. 18. No. 1, March 2012
3. When should liver biopsy be performed in patients with
chronic liver disease for the diagnosis of LC?
- Liver biopsy should be selectively performed to detect the
cause of LC and assess the disease activity and fibrosis.
Liver biopsy is necessary on patients in whom the
diagnosis remains unclear from the conventional test (B1)
2. Anti-fibrotic therapy for LC
LC is a pathological condition of liver fibrosis generated
by continuous scar formation and recovery due to chronic
liver injury, eventually leading to the development of
regenerative nodules around the fibrotic scar.13 If liver
injury is chronically repeated, damaged liver cells cannot
regenerate and instead migrate to the extracellular matrix
such as collagen.14 The mechanism of liver fibrosis is
variable, depending on causes such as alcohol, hepatitis
virus, or bile acids. Hepatic stellate cells, which are located
in the space of Disse, play a major role in liver fibrosis.14
Histological changes associated with LC have long been
believed to be irreversible. However, in patients receiving
antiviral therapy for CHB, liver fibrosis has been observed
to be significantly improved.15 Similarly, the primary approach
to treating LC is treatment of the underlying disease. The
second approach in the treatment of LC is anti-fibrotic
therapy that targets the liver fibrosis-generating mechanism
irrespective of the cause of LC. In order to develop effective
treatments for liver fibrosis, the molecular pathogenesis
and treatment of liver fibrosis have been exhaustively
investigated over the last 2 decades. Subsequently, a number
of substances or drugs with anti-fibrotic effects in animal
experiments have been found; however, most of these have
not been verified for use in human beings.
2-1. Chronic hepatitis B
Antiviral therapy that regulates inflammation via the
inhibition of viral proliferation is recommended for improving
liver fibrosis.15-21 There were no significant differences in
the degree of improvement in fibrosis according to antiviral
drugs.22-24 As liver fibrosis progresses, the rate of improvement
by antiviral treatment increases.18,25 Therefore, in patients
with advanced liver fibrosis, antiviral treatment is needed in
the case with viral proliferation. In patients with LC due to
CHB, antiviral therapy with a sufficient treatment period
can be recommended to reduce liver fibrosis from virus
proliferation. However, in the case of drug-resistant viral
infection, the benefits of antiviral treatment are reduced.19,22,26
The extent of liver fibrosis was reduced by 49% when
treated with interferon α or peginterferon α.20 In patients
with HBeAg-positive CHB, hepatic fibrosis improved in
39% of patients after initial treatment with entecavir, whereas
in HBeAg-negative CHB, improvement was observed in
36% of patients.23,27 With 1-year tenofovir treatment, inflam-
mation improved without aggravation in 74% of HBeAg-
positive CHB patients and in 71% of HBeAg-negative CHB
2-2. Chronic hepatitis C
Interferon treatment for CHC reduces the hepatic necrotic
inflammatory reaction; particularly, in patients with a
sustained virological response, the reductions in serum
hepatitis C virus RNA and intrahepatic necrotic inflammatory
reactions are correlated.29 In particular, antiviral treatment
should be actively considered for patients presenting with
genotype 2 or 3 and a Child-Pugh score <7. In patients
with a Child-Pugh score of 7-9, antiviral treatment can be
considered with careful attention to hepatic dysfunction.30-34
2-3. Alcohol
Abstinence is the most important treatment of alcoholic
liver disease.35 Abstinence not only improves fibrosis in
hepatic tissue but also reduces portal pressure and inhibits
progression to LC. Ultimately, the survival rate of patients in
all stages of alcoholic liver disease increases following
abstinence, with improvements being observed in up to 66%
of patients.35 Sustained drinking increases the risk of
variceal bleeding by portal hypertension and is closely
related with mortality.
In severe alcoholic hepatitis, steroid and pentoxifylline
therapy have been recommended by several studies. However,
the effect of these drugs on fibrosis has not been confirmed;
therefore, these medications are not recommended in the
treatment of fibrosis as anti-fibrotic therapy.
2-4. Nonalcoholic fatty liver
Treatment of nonalcoholic fatty liver comprises improving
insulin resistance, removing risk factors of metabolic
syndrome, lifestyle modifications, drug therapy, and operative
treatment.36-52 Weight loss appears to help in liver steatosis
as well as relieves hepatic inflammation and fibrosis.36-39
Therefore, the first choice of therapy in nonalcoholic fatty
liver disease is weight loss through diet therapy and lifestyle
Page 5
Ki Tae Suk, et al. Revision and update on clinical practice guideline for liver cirrhosis 5
1. What is anti-fibrotic therapy according to the causes of LC?
- In patients with LC, it is recommended that the cause of
disease should be treated to improve liver fibrosis. (A1)
- In patients with LC due to CHB, antiviral therapy with a
sufficient treatment period can be recommended to reduce
liver fibrosis from virus proliferation. (B1)
- In patients with LC due to CHC, antiviral therapy with a
combination of peginterferon and ribavirin can be
recommended, if the normal range of liver function with
viral proliferation. In addition, monitoring for side effects
is needed. (B1)
- In patients with alcoholic LC, strict abstinence is
recommended to prevent worsening of disease. (A1)
- In patients with nonalcoholic fatty liver disease, losing
weight, diet therapy, and exercise can be recommended.
- In patients with primary biliary cirrhosis, ursodeoxycholic
acid is recommended with a dose of 13-15 mg/kg/day.
1. What is the role of endoscopy in patients with LC?
- It is recommended that all patients undergo endoscopy
when they are first diagnosed with LC in order to
evaluate the presence of esophageal varix and the risk of
bleeding. (A1)
- Esophageal varices are classified into small (F1) and large
(F2 and F3). Also, red color sign should be checked during
endoscopy. (B1)
- For patients with compensated LC should be considered
for endoscopy every 2 to 3 years, and patients with
decompensated LC every 1 to 2 years in order to evaluate
the occurrence and progression of varices. (B1)
- Patients with compensated LC with small varices not
using nonselective beta-blocker, should be considered for
endoscopy every 2 years to evaluate the progression of
varices. (B1)
- The frequency of endoscopy can be adjusted according to
the cause and progression of LC.
modifications, with more than 7% weight loss being the
recommended target.39 For nonalcoholic fatty liver disease,
clinical trials using multiple drugs have currently being
attempted. However, data regarding its effectiveness, safety,
and dosing period remain limited.40
2-5. Primary biliary cirrhosis
Ursodeoxycholic acid has been proven to improve
primary biliary cirrhosis and is the only drug recognized for
its treatment.53-56 Ursodeoxycholic acid reduces serum
bilirubin levels, which is an important prognostic factor, and
delays the progression and deterioration of fibrosis55,56
13-15 mg/kg/day is the most effective dose in terms of
biological effect and cost-effectiveness. Improvements of
liver function tests appear within 6-9 months of therapy in
more than 90% of patients.57 Ursodeoxycholic acid treatment
is not known to improve fatigue, itching, bone diseases, or
autoimmune reactions associated with primary biliary
3. Variceal bleeding
Esophageal variceal bleeding is found in approximately
40% of patients with Child-Pugh A class LC, and in
approximately 80% of patients with Child-Pugh C class
LC.58 The risk of variceal bleeding depends on the size of
varices, red color sign, and the Child-Pugh classification.
Variceal bleeding due to portal hypertension can be prevented
when the value of hepatic venous pressure gradient is lower
than 12 mmHg or when it is decreased to lower than 20% of
the baseline measurement.59
3-1. Diagnosis
It is recommended that all patients undergo endoscopy
when they are first diagnosed with LC in order to evaluate
the presence of esophageal varix and the risk of bleeding.60
Esophageal varices are classified based on the diameter of
varices and their morphology as follows: varices with the
findings of larger than 5 mm61 or F2-F3 (beaded varices -
crystalled varices) are defined as large and varices with the
findings of smaller than 5 mm or F1 (straight varices) are
defined as small.62 Treatment to prevent esophageal variceal
bleeding should be performed when large varices are
present. For patients with compensated LC should be
considered for endoscopy every 2 to 3 years, and patients
with decompensated LC every 1 to 2 years in order to
evaluate the occurrence and progression of varix.63 Patients
with compensated LC with small varices not using
nonselective beta-blocker, should be considered for
endoscopy every 2 years to evaluate the progression of
3-2. Acute esophageal variceal bleeding
3-2-1. Definition and diagnosis
Acute variceal bleeding is defined as hematemesis within
last 24 hours of presentation, and/or ongoing melena, with
the last melenic stool within last 24 hours before the hospital
visit in a known or suspected case of portal hypertension.
Page 6
6 The Korean Journal of Hepatology Vol. 18. No. 1, March 2012
Table 2. Drugs for acute esophageal variceal bleeding
TypeEffectDose, usage, duration
TerlipressinSide effect (cardiac ischemia)
Improve survival rate
Effect on hepatorenal syndrome
Inject 2 mg at first and inject 1-2 mg every 4-6 hours
until control bleeding or use for 3 days
SomatostatinSide effects
(intestinal vessel constriction, vomiting, or hyperglycemia)
Do not improve survival rate
Somatostatin: IV 250 μg at first and 250 μg/hour for
2-3 days
AntibioticsReduce bacterial infection
Improve survival rate
Ceftriaxone: IV 1g/day for 5-7 days
Norfloxacin: PO 400 mg twice a day for 5-7 days
2. How should acute variceal bleeding be treated?
- It is recommended that patients with acute variceal
bleeding initially be administered vasoconstrictor and
antibiotic treatment. (A1)
- Endoscopic treatment is recommended for patients with
acute variceal bleeding. (A1)
- TIPS can be recommended if drugs and endoscopic therapy
have failed or endoscopic treatment is impossible. (B1)
Endoscopy is the most definite diagnostic method for
identifying acute esophageal variceal bleeding. Variceal
bleeding can be diagnosed as follows: direct visualization of
blood issuing from esophageal varices, presence of signs of
recent bleeds on varices such as white nipple sign or
overlying clot, or presence of blood in the stomach in the
absence of another source of bleeding.64
3-2-2. Treatment
The first line of therapy includes vasoconstrictors such as
terlipressin and somatostatin.65 Antibiotics are recommended
for patients admitted in the hospital.66 Antibiotic therapy is
recommended for 5-7 days to prevent sepsis and rebleeding
following endoscopy (Table 2).67
Medication and endoscopic therapy are recommended in
patients with acute variceal bleeding for the first time.68 If
active bleeding is present, banding of the culprit vessel or
that just below the ooze should be performed endoscopically.
After ligation of the active bleeding site, even in the absence
of active bleeding, banding should be performed starting
from just above the gastro-esophageal junction (5-10 mm)
in a sequential manner up to 5 cm. Endoscopic injection
sclerotherapy is recommended if endoscopic variceal ligation
is technically impossible or has failed.
Balloon tamponade can be used as a rescue therapy if
active variceal bleeding cannot be controlled. Transjugular
intrahepatic portosystemic shunt (TIPS) is recommended
if medication and endoscopic therapy have failed or if
endoscopic therapy is impossible.
3-3. Prevention
3-3-1. Prevention of first bleeding in patients without
esophageal varices
Nonselective beta-blockers are not recommended in
patients without esophageal varices.69,70
3-3-2. Prevention of first bleeding in patients with small
esophageal varices
Nonselective beta-blockers do not lower the incidence
of bleeding in patients with small esophageal varices.71
However, patients with a high risk of bleeding (Child-Pugh
class B/C or endoscopic red color sign), are considered for
nonselective beta-blocker therapy.70 The dose of nonselec-
tive beta-blockers is adjusted for a reduction in the resting
heart rate by 25%, to 55 beats/minute, or until the occurrence
of side effects. In Koreans, the mean adjusted dose of
propranolol is 160 mg/day.72,73
3-3-3. Prevention of first bleeding in patients with large
esophageal varices
In large esophageal varices, endoscopic variceal ligation
(EVL) and nonselective beta-blockers are effective in
preventing the first bleeding occurrence.74,75 In patients with
large varices (F2 or F3), which have never been observed to
bleed, nonselective beta-blockers or EVL is recommended.
Repeated EVL is recommended until the disappearance
of esophageal varices.76 Low doses of carvedilol have been
shown to lower the frequency of variceal bleeding
Page 7
Ki Tae Suk, et al. Revision and update on clinical practice guideline for liver cirrhosis 7
3. How can a first variceal bleeding be prevented in patients
with LC?
- In patients without varices, a nonselective beta-blockers
are not recommended for the purpose of preventing the
formation of varix and first bleeding of esophageal varix.
- Nonselective beta-blockers should be considered for
patients with small varices which have never bled but
have a high risk of bleeding (Child-Pugh class B/C or red
color sign on endoscopy). (B1)
- In patients with large varices (F2 or F3) in which bleeding
has never been observed, nonselective beta-blockers or
EVL are recommended. (A1)
4. How should nonselective beta-blockers be administered to
patients with LC?
- Nonselective beta-blockers are adjusted at the dose of
reduction in resting heart rate by 25% or 55 beats/minute,
or until the side effects occur. (B1)
5. How to prevent recurrence of variceal bleeding?
- Patients who experience acute variceal bleeding need
treatment to prevent rebleeding. (A1)
- EVL alone or in combination with nonselective
beta-blockers should be considered for the prevention of
rebleeding. (B1)
- TIPS should be considered as a rescue therapy in Child-
Pugh A/B patients in whom other therapies have failed.
- Liver transplantation should be considered for patients
who meet indications for liver transplantation. (B1)
with lesser side effects as compared with EVL. However,
additional research is needed before they can be routinely
used.66,77 Combination therapy with EVL and nonselective
beta-blockers for the prevention of first bleeding has shown
no differences as compared with monotherapy.78
3-4. Prevention of variceal rebleeding
3-4-1. Definition and diagnosis
Variceal rebleeding is defined as bleeding after 5 days of
recovery from acute variceal bleeding.70 It is diagnosed
similar to acute variceal bleeding.
3-4-2. Prevention
Nonselective beta-blockers alone or combination therapy
with isosorbide mononitrate are known to be effective in the
prevention of rebleeding.79 EVL shows better outcomes than
endoscopic injection sclerotherapy in endoscopic therapy
for prevention of rebleeding.80 Rebleeding has been reported
in 32% of patients after EVL. Combination therapy of EVL
and nonselective beta-blockers has been shown to have
better outcomes than EVL alone.81,82
TIPS shows a significantly low rebleeding rate as compared
with endoscopic therapy. However, it shows a significantly
high incidence of hepatic encephalopathy. TIPS is not
recommended as a first-line therapy for esophageal variceal
bleeding and is recommended only as a rescue therapy when
combination therapy fails.83 Liver transplantation should be
considered for patients who meet indications for liver
If the hepatic venous pressure gradient is reduced to less
than 12 mmHg or to more than 20% reduction in baseline
levels by medical therapy, the incidence rate of rebleeding is
low (10%).86 In such cases, further endoscopic therapy may
not be required.
3-5. Gastric varices
3-5-1. Definition and diagnosis
Gastric varices are enlarged submucosal veins of the
stomach that cause critical upper gastrointestinal bleeding.
Gastric varices occur in approximately 20% of patients with
portal hypertension, and the bleeding rate in 2 years is
known to be 25%.87 Diagnosis is performed by endoscopy.
Endoscopic ultrasound can also be helpful.88
3-5-2. Classification
Gastroesophageal varices are classified depending on
whether esophageal varices are extended along lesser
curvature (gastroesophageal varices, GOV1) or gastric
fundus (GOV2). Gastric varices alone are classified as
varices located in the fundus (isolated gastric varices, IGV1)
and any other regions, i.e., stomach or duodenum (IGV2).87
3-5-3. Treatment and prevention
EVL is recommended for the treatment of GOV1.
Endoscopic variceal obturation (EVO) can be an alter-
native.89-93 EVO involves the injection of tissue adhesives
such as N-butyl-2-cyanoacrylate (histoacrylⓇ) into the
varices via endoscopy and can be recommended in treating
GOV2 and IGV.91,94-96 Endoscopic injection sclerotherapy is
not recommended in treating GOV2 or IGV1 because of its
low rate of hemostasis, high rate of rebleeding, and other
complications.97-100 If endoscopic treatment is not possible,
Page 8
8 The Korean Journal of Hepatology Vol. 18. No. 1, March 2012
6. How should gastric variceal bleeding be treated?
- In gastric variceal bleeding, EVL or EVO are considered
for GOV1 accompanying esophageal varices extended
along the lesser curvature. (B1)
- EVO is preferable in patients with GOV2 or IGV1. If
endoscopic treatment is not possible, TIPS can be used. If
gastric varix is accompanied with gastrorenal shunt,
balloon-occluded retrograde transvenous obliteration can
be considered. (B1)
- Surgery such as distal splenorenal shunt or vascular shunt
should be considered for patients (Child-Pugh A/B) and
liver transplantation for patients (Child-Pugh B/C) who
are not eligible for endoscopic treatment.
7. How should portal hypertensive gastropathy be treated?
- If chronic bleeding due to portal hypertensive gastropathy
presents, nonselective beta-blockers can be used. (B1)
1. How should ascites of LC be diagnosed?
- Paracentesis should be performed when Grade 2 or 3
ascites occurs, when there is clinical suspicion of
infection, or when there are complications of LC such as
encephalopathy or kidney dysfunction. (A1)
- When the initial paracentesis is performed, a total cell
count and differential, albumin, and total protein tests
should be performed. A culture of ascitic fluid in blood
culture bottles at the bedside is recommended. (A1)
- If serum-ascites albumin gradient is greater than or equal
to 1.1 g/dL, it indicates ascites by portal hypertension. (B1)
TIPS can be performed.101,102 If a gastrorenal shunt is
present, balloon-occluded retrograde transvenous obliteration
can be performed.103-106 Surgery, such as distal splenorenal
shunting or vascular shunting, can be attempted if endoscopic
treatment is not possible in case of Child-Pugh A/B patients,
while liver transplantation is considered in the case of
Child-Pugh B/C patients.107
Empirical use of nonselective beta-blockers, balloon-
occluded retrograde transvenous obliteration, and EVO can
prevent first gastric variceal bleeding, while EVO, TIPS,
and balloon-occluded retrograde transvenous obliteration
are considered to prevent gastric variceal rebleeding.70,108
3-6. Portal hypertensive gastropathy
3-6-1. Diagnosis
Portal hypertensive gastropathy is diagnosed when gastric
mucosal changes of snake-skin appearance (or mosaic
pattern) are found on endoscopy in patients with portal
hypertension.109 When gastric mucosal changes alone are
found, this is diagnosed as a mild form. When red or dark
brown viscous changes with changes in gastric mucosa are
found, it is considered severe.72 Severe portal hypertensive
gastropathy causes more chronic bleeding than does the mild
3-6-2. Treatment
In chronic bleeding due to portal hypertensive gastropathy,
the goal of treatment is lowering the portal pressure with
nonselective beta-blockers. In addition, iron supplementation
is recommended.111 Despite these treatments, if repeated
transfusions are needed for the treatment of chronic anemia,
TIPS can be considered.112
4. Ascites
Ascites is the most common complication in LC,
occurring in 60% of the patients with compensated LC
within 10 years.113 Ascites appears in 2/3 of the patients who
required admission due to LC,114 and 60% of the patients
requiring paracentesis is because of LC.115
4-1. Diagnosis
Abdominal ultrasound can diagnose ascites with only 100
mL.116 Ascites is classified by the amount of fluid as follows:
Grade 1 is diagnosed through imaging study, Grade 2
through inspection and physical examination, Grade 3 based
on marked abdominal expansion. Paracentesis is the most
useful and simple diagnostic tool in Grade 2 or 3 ascites.
Furthermore, paracentesis should be performed in cirrhotic
patients with fever, abdominal pain, bleeding, encephalopathy,
hypotension, or kidney dysfunction to assess for spontaneous
bacterial peritonitis (SBP), since 10-27% of the patients with
ascites have SBP.117 The main purpose of paracentesis is to
discriminate the cause of ascites. Therefore, screening tests
should include total cell count and differential, albumin, and
total protein. Blood cell count is the most useful test for
diagnosing SBP. For differential diagnosis of ascites, a
serum-ascites albumin gradient can be calculated. If the
serum-ascites albumin gradient is is greater than of equal to
1.1 g/dL, ascites is ascribed to portal hypertension with an
accuracy of 97%.
Page 9
Ki Tae Suk, et al. Revision and update on clinical practice guideline for liver cirrhosis 9
Table 3. Treatment of ascites depending on the grade
Grade 1, mildGrade 2, moderate Grade 3, severe
Low-salt diet●○○
Large volume paracentesis●
Grade 1, a small amount of ascites detected in the ultrasound test; Grade 2, ascites of the amount which distends abdomen
symmetrically; Grade 3, ascites of the large volume which distends abdomen; ●, major treatment; ○, recommended.
4-2. Treatment
Although controversial,118 a low salt diet is considered
effective for controlling ascites and shortening hospitalization.
Less than 5 g/day of salt (sodium for 2 g, 88 mEq) is
recommended. When plasma sodium is lower than 120-125
mEq/L, water intake should be restricted to 1-1.5 L/day.119
4-2-1. Medications
If severe ascites is present, diuretic therapy should be used
for negative sodium balance.120,121 Secondary hyperaldo-
steronism in patients with LC induces reabsorption of
sodium and water in the distal renal tubule and collecting
tubule, consequently causing hypokalemia. Aldosterone
antagonists inhibit this mechanism, and hence is mainly
used for controlling ascites in patients with LC. Spirono-
lactone has a long half-life but has a slow onset of action,
and therefore requires 3-4 days to achieve a stable
concentration. It is initiated at a dose of 50-100 mg/day, with
a maximum dose of 400 mg/day. Side effects include
hyperkalemia, gynecomastia, mastalgia, hyposexuality, and
erectile dysfunction.122
Loop diuretics operate by blocking Na-K-2Cl receptors in
the thick ascending limb of Henle's loop. They are mostly
used along with aldosterone antagonists in patients with LC.
Hypokalemia may occur as a side effect, but via such
mechanism, hyperkalemia caused by the aldosterone anta-
gonist can be corrected. The starting dose is 20-40 mg/day,
with the maximum dose being 160 mg/day. Monotherapy
with loop diuretics is less effective than aldosterone anta-
gonist monotherapy. Spironolactone monotherapy can be
used initially on patients with ascites.123 Combination
therapy of an aldosterone antagonist and a loop diuretic is
recommended at first in a ratio of 100:40, which stabilizes
plasma potassium levels. Combination therapy shows a
faster effect in controlling ascites and lowers the possibility
of hyperkalemia as compared to aldosterone monotherapy.124
When peripheral edema is present, the rate of weight loss
should be no greater than 1 kg/day. For patients without
edema, 0.5 kg/day of weight loss is ideal.120,125 If there is no
weight loss even with 5 g/day of salt intake, the diet and
diuretic dose should be evaluated by examining the amount
of urinary sodium excretion per day.120,126 Patients with low
salt intake should not excrete more than 78 mEq of urinal
sodium in 24 hours. In such patients, if urinary sodium
excretion is more than 78 mEq, low salt intake is judged not
to be followed. When the excretion is less than 78 mEq, the
diuretic is considered to be inadequate and the dose needs
to be increased. Spot urine Na/K ratio of more than 1 repre-
sents 24 hours urine sodium excretion more than 78 mEq.127
It is important to check the weight loss, vital sign, changes
in consciousness level, and the level of plasma sodium,
potassium, and creatinine during diuretic administration.
When plasma sodium is more than 126 mEq/L, diuretics can
be used without the restriction of water intake. However,
when plasma sodium is less than 125 mEq/L, the physician
should consider cessation or reduction in the dose of the
diuretic and restriction of water intake. If plasma sodium is
less than 120 mEq/L, the diuretic and water intake should be
stopped and a plasma expander such as albumin should be
administered. If plasma sodium is less than 125 mEq/L with
kidney dysfunction, the diuretic should be stopped and a
plasma expander should be administered.128 If plasma
potassium is less than 3.5 mEq/L, the dose of loop diuretic
should be reduced or stopped. If plasma potassium is more
than 5.5 mEq/L, the dose of aldosterone antagonist should
be reduced. And if plasma potassium is more than 6.0
mEq/L, the aldosterone antagonist should be ceased.120
4-2-2. Therapeutic paracentesis (reference to intractable
ascites section)
Therapeutic paracentesis is an effective treatment for
tension-type ascites, because it relieves the symptoms more
quickly than diuretics and shortens hospitalization
(Table 3).129
Page 10
10 The Korean Journal of Hepatology Vol. 18. No. 1, March 2012
2. How should ascites of LC be treated?
- Patients with cirrhotic ascites should be advised to take in
less than 5 g of salt a day. (B1)
- When the serum sodium is normal, restriction of water
intake is not necessary. (B1)
- Bed rest is not recommended for the treatment of ascites.
- The first-choice diuretic for patients with cirrhotic ascites
is aldosterone antagonist. (A1) Loop diuretics can be used
along with aldosterone antagonist. (B1) Spironolactone
can be used with a starting dose of 50-100 mg/day up to
400 mg/day. To increase the diuretic effects and maintain
a normal serum potassium level, 20-40 mg of furosemide
should be used with spironolactone (40:100) beginning at
the initial stage.
- When peripheral edema is present, the rate of weight loss
should be recommended up to 1 kg/day. For patients
without edema, 0.5 kg/day of weight loss should be
recommended. (A1)
- In cases of severe hyponatremia, kidney dysfunction,
encephalopathy, or severe muscle spasms, diuretics should
be stopped. (B1)
- In cases of hypokalemia, loop diuretic should be reduced
or stopped, and if hyperkalemia occurs, the dose of
aldosterone antagonist should be adjusted. (B1)
- Therapeutic large volume paracentesis is recommended as
the first-line treatment for tension-type ascites. (A1)
Table 4. Definition and diagnosis of refractory ascites206
Diuretic resistant ascitesBeing not responsive to sodium limit and diuretic, ascites is not controlled, and recurs early
Diuretic intractable ascites Since sufficient amount of diuretic cannot be given for its complication, ascites is not controlled, and
recurs early
Required conditions
Treatment periodFor over a week, give sufficient amount of diuretics (spironolactone 400 mg/day and furosemide 160
mg/day) and restriction of sodium intake to 5 g/day
Treatment responseBody weight loss is less than 800 g during 4 days, and the amount of urine sodium excretion is less
than the amount taken
Early recurrence of ascite Within 4 weeks after paracentesis, grade 2 or 3 ascites recurs
Complications Hepatic encephalopathy
Renal dysfunction: after giving diuretics, serum creatinine goes up over 100%, and exceeds 2.0 mg/dL
Hyponatremia: serum sodium reduces by over 10 mEq/L, and goes down below 125 mEq/L
Hypokalemia or hyperkalemia: serum potassium goes down below 3 mEq/L, or goes up beyond 6 mEq/L
4-3. Refractory ascites and hyponatremia
4-3-1. Refractory ascites
Refractory ascites130 is defined as fluid overload that (1) is
not controlled despite restriction of sodium intake and the
maximum dose of diuretics, and (2) recurs rapidly after
paracentesis. There are 2 types of refractory ascites-diuretic
resistant and diuretic intractable (Table 4).
Large-volume paracentesis is not considered for every
patient as a first-line treatment. It can be selectively
performed in occasions in which the patient has difficulties
eating or breathing because of abdominal distension. After
relieving the symptoms by paracentesis, the maintenance
treatment should be administered. In the case of large-
volume paracentesis over 5 L, an infusion of 8-10 g of
albumin per L is recommended. In the case of paracentesis
less than 5 L, although the occurrence of circulatory
dysfunction is not frequent, an infusion of volume expander
can be considered. Albumin can also be used for this
purpose.125,131 Medications such as midodrine,132 norad-
renaline,133 or terlipressin134 can be used. Compared with
repetitive paracenteses, TIPS is an effective method to
prevent the recurrence of ascites and the occurrence
hepatorenal syndrome. However, hepatic encephalopathy
occurs in 30-50% of cases after TIPS. As 21% of the patients
with refractory ascites die within 6 months and the median
survival period is also less than 1 year, they should be
considered for liver transplantation.135
4-3-2. Hyponatremia
The diagnostic criterion for hyponatremia is less than 130
mEq/L.119 A hypervolemic state can be corrected to normal
by a negative water balance. Eventually, dilutional
hyponatremia can be improved.136 Restriction of water
intake can prevent a decrease in the serum sodium level.125
Hypertonic sodium injection can worsen ascites and
edema.137 Plasma expanders can be useful in the treatment of
hyponatremia.138 Vaptan,139 a selective vasopressin 2 receptor
antagonist of arginine vasopressin, leads to the excretion of
Page 11
Ki Tae Suk, et al. Revision and update on clinical practice guideline for liver cirrhosis 11
3. How should intractable ascites be treated?
- Repetitive large volume paracentesis is recommended in
patients with refractory ascites. (A1)
- In the case of large volume paracentesis, 8-10 g/L (albumin/
ascites) is recommended for the prevention of postparacentesis
circulation dysfunction. (A1)
- TIPS can be used for the treatment of refractory ascites. (B1)
- Because of poor prognosis, liver transplantation is
recommended in patients with refractory ascites. (A1)
- If the serum sodium concentration is less than 120-125
mEq/L, restriction of fluid intake to 1-1.5 L/day is recom-
mended. (A1)
- Albumin or vaptan can be used in severe dilutional hypo-
natremia (<125 mEq/L). (B2)
Table 5. New International Ascites Club's diagnostic criteria of hepatorenal syndrome
1) Cirrhosis with ascites
2) Serum creatinine >133 mmol/L (1.5 mg/dL)
3) No improvement of serum creatinine (decrease to a level of 133 mmol/L) after at least 2 days with diuretic withdrawal and volume
expansion with albumin; the recommended dose of albumin is 1 g/kg of body weight per day up to a maximum of 100 g/day
4) Absence of shock
5) No current or recent treatment with nephrotoxic drugs
6) Absence of parenchymal kidney disease as indicated by proteinuria >500 mg/day, microhematuria (>50 red blood cells/high-power
field), and/or abnormal renal ultrasound.
solute-free water. This agent can be used in the treatment of
hyponatremia caused by inappropriate antidiuretic hormone
secretion, heart failure, or liver cirrhosis. In the United
States and Europe, tolvaptan and conivaptan are approved
for the treatment of severe hyponatremia (<125 mEq/L).
4-4. Hepatorenal syndrome
4-4-1. Definition and diagnosis
Renal failure in LC occurs in 2 forms. First, type 1
hepatorenal syndrome is a rapid progressive acute renal
dysfunction which occurs due to the strong contraction of
the renal vasculature. Type 2 hepatorenal syndrome is a
relatively slow process with a rather moderate renal
dysfunction. The most important mechanism involved in the
occurrence of hepatorenal syndrome is decreased effective
blood volume due to the dilation of the splanchnic and
peripheral circulation. This situation activates the sympathetic
nervous system as well as the renin-angiotensin system and
causes functional renal disorder.140-142
In 1994, the International Ascites Club announced the
diagnostic criteria for hepatorenal syndrome; in 2007,
they revised these criteria to providing clearer diagnostic
methods and including infectious diseases (Table 5).130,143
4-4-2. Treatment
Dilatation of splanchnic artery and decrease in effective
arterial blood volume arethe primary mechanisms of
hepatorenal syndrome. The effect of albumin monotherapy
is not sufficient in this situation.144,145 Vasoconstrictors have
been used in the treatment of the hepatorenal syndrome, and
combination therapy with vasoconstrictors and albumin is
effective in hepatorenal syndrome. The combination therapy
of terlipressin and albumin improves renal function in
60-75% of the patients.144,146-152 Maintenance therapy is
possible up to 15 days or until the serum creatinine
levels decrease (<1.5 mg/dL). Further, long-term usage
(approximately 2 months) can be considered as a bridging
therapy prior to liver transplantation.153,154 The combination
therapy of noradrenaline and albumin can also improve
renal function in hepatorenal syndrome.155,156 Combination
therapy of midodrine and octreotide or triple therapy of
midodrine, octreotide, and albumin also meaningfully improve
renal function in patients with hepatorenal syndrome.157-160
After administration of terlipressin, hepatic venous
pressure gradient is known to decrease while the renal blood
flow increases.161,162 Therefore, it can also be used for
treatment in patients with secondary renal insufficiency due
to variceal bleeding.147,163,164
Although TIPS157,165,166 reduces the serum creatinine
levels in most patients with hepatorenal syndrome, the effect
is slower than the combined use of terlipressin and albumin.
In a group that used molecular adsorbent recirculating
system167 in the treatment of hepatorenal syndrome,
laboratory findings (serum creatinine, bilirubin, and
prothrombin time) and 30-days survival rate were improved
compared to the group that underwent intermittent dialysis
and drug therapy. Continuous arterio-venous hemofiltration
and continuous veno-venous hemofiltration can be considered
to minimize the changes in blood pressure.168,169
Page 12
12 The Korean Journal of Hepatology Vol. 18. No. 1, March 2012
4. How should hepatorenal syndrome be treated?
- In type 1 hepatorenal syndrome, combination therapy of
terlipressin and albumin can improve renal function. (A1)
- In type 1 hepatorenal syndrome, combination therapy of
midodrine, octreotide, and albumin can be considered.
- The best treatment for type 1 hepatorenal syndrome is
liver transplantation. (A1)
- In high risk patients who have ascites accompanied by
SBP, the use of albumin can decrease the incidence of
hepatorenal syndrome. (A1)
5. How should SBP be diagnosed and treated?
- If SBP is suspected and the result of paracentesis show a
PMN of more than 250/mm3, empirical antibiotic therapy
should be started immediately without results of ascitic
fluid culture. (A1)
- Third-generation cephalosporine is recommended as an
initial antibiotic. (A1)
- The patient with symptoms or signs of infection should
receive empirical antibiotics while awaiting of ascitic fluid
culture even if the number of PMN is less than 250/mm3.
- If the secondary bactrieal peritonitisis suspected, an
imaging study such as a CT should be performed (A1),
and additional examinations such as those for total
protein, LDH, glucose, or gram staining can be performed.
- If the patient has a history of SBP, gastrointestinal bleeding,
or protein in ascites less than 1.5 g/dL, although there is no
gastrointestinal bleeding, prophylactic antibiotics should
be considered because the chance of SBP is high. (B1)
4-4-3. Prevention
Hepatorenal syndrome can be prevented by inhibiting the
decrease of plasma volume. Diuretics and lactulose should
be used carefully to prevent excessive fluid loss.132,133,170,171
In patients with SBP, the use of albumin and antibiotics
reduce the incidence of hepatorenal syndrome.172,173 The use
of oral norfloxacin has been shown to reduce the occurrence
of hepatorenal syndrome and increase 3-month survival
rates in patients with low serum protein (<1.5 g/dL) or renal
insufficiency (creatinine ≥1.2 mg/dL, or blood urea nitrogen
≥25 mg/dL, or serum Na ≤130 mEq/L).174 Administration of
pentoxifylline improved survival rates as compared to
corticosteroids in severe acute alcoholic hepatitis patients
(Maddrey's discriminant factor ≥32).175-177
4-5. Spontaneous bacterial peritonitis
4-5-1. Definition and diagnosis
SBP is bacterial infection of ascites, without an evident
intra-abdominal, surgically treatable source of infection. It
occurs in 10-30% of the patients with cirrhotic ascites and
recurs in 70% of the patients within 1 year even if
SBP can be diagnosed in patients with findings of ascitic
polymorphonuclear leukocyte (PMN) ≥250/mm3and bacteria
in the ascitic culture without an evident intra-abdominal
infection. If ascites fluid contains red blood cells, PMN is
calculated by subtracting 1/mm3 per red blood cell 750
/mm3. Culture-negative neutrocytic ascites is a condition
where ascitic PMN ≥250/mm3 but no cultured bacteria are
observed. These patients show a clinical course mostly
similar to patients with SBP. Empiric antibiotics treatment is
recommended. Monomicrobial non-neutrocytic bacterascites
is a condition with ascitic PMN <250/mm3, but cultured
single-strain bacteria being observed.
4-5-2. Treatment
Administration of third generation cephalosporin is
recommended. Cefotaxime is recommended at a dose of 2 g
every 6-8 hours by intravenous injection. Subsequently,
selective antibiotic therapy based on the result of ascites
culture should be administered for 5-10 days.179 Treatment
duration varies according to the symptoms and/or results of
antibiotic sensitivity. Albumin during the treatment of SBP,
especially in patients with renal dysfunction, can be
4-5-3. Prevention
If a patient presentsacute gastrointestinal bleeding,
administration of norfloxacin at a dose of 400 mg twice daily
for 7 days orally or ceftriaxone at a dose of 1 g daily for
7 days intravenously is effective in preventing SBP. In
patients with a concentration of protein in ascites fluid less
than 1.5 g/dL or bilirubin in plasma is more than 2.5 mg/dL,
administration of norfloxacin at a dose of 400 mg daily for
longer than 6 months orally is effective in prolonging the
5. Hepatic encephalopathy
5-1. Definition
Hepatic encephalopathy is a neuropsychiatric syndrome
that follows liver dysfunction. Patients with hepatic
encephalopathy can show various neurological illnesses
Page 13
Ki Tae Suk, et al. Revision and update on clinical practice guideline for liver cirrhosis 13
Table 6. Classification of hepatic encephalopathy180
HE typeNomenclature SubcategorySubdivisions
AEncephalopathy associated with acute liver failure
B Encephalopathy associated with portal-systemic bypass and no intrinsic
hepatocellular disease
CEncepahlopathy associated with cirrhosis and portal hypertension/or
systemic shunts
Episodic HEPrecipitated
Persistent HEMild
Minimal HE
HE, hepatic encephalopathy.
Table 7. West-Haven criteria for hepatic encephalopathy183
GradeConsciousness Intellect and behaviorNeurologic findings
0 NormalNormalNormal examination; if impaired psychomotor
testing then MHE
1 Mild lack of awarenessShortened attention span; impaired
addition or subtraction
Mild asterixis or tremor
2Lethargic Disoriented; inappropriate behaviorObvious asterixis; slurred speech
3 Somnolent but arousableGross disorientation; bizarre behavior Muscular rigidity and clonus; hyperreflexia
4 Coma ComaDecerebrate posturing
MHE, minimal hepatic encephalopathy.
such as cognition and orientation disorders. Hepatic
encephalopathy is classified into 3 groups according to the
causative liver disease (Table 6).180,181
5-2. Diagnosis
Hepatic encephalopathy is generally accompanied by
advanced liver disease; therefore, muscle weakness, jaundice,
ascites, palmar erythema, edema, spider telangiectasias, and
fetor hepaticus can be noted on physical examination.
Clinicians should check for gastrointestinal hemorrhage,
uremia, use of anti-psychotics or diuretics, protein hyper-
ingestion, infection, constipation, dehydration, electrolyte
imbalance, etc.182 Common symptoms include concentration
disorders, sleep disorders, and movement disorders, including
lethargy or coma. The severity of hepatic encephalopathy
can be evaluated using the West Haven criteria (Table 7).183
Venous levels of ammonia are not helpful because they
are not proportional to the severity of hepatic encephalopathy
and some patients with sever hepatic encephalopathy have
normal venous ammonia levels.184
Brain MRI is considered better than brain CT in the
diagnosis of brain edema accompanying hepatic failure, but
this is not true for hepatic encephalopathy. Brain CT is
useful when differentiating between organic causes of
neuropsychiatric disorders such as intracranial hemorrhage.185
5-3. Treatment
The goal of treatment is to prevent secondary damage
caused by decreased consciousness, normalize the patient's
state of consciousness, prevent recurrence, and to improve
the prognosis and quality of life by eliminating the social
and economic restrictions caused by hepatic encephalopathy.
The precipitating factor can be identified in more than 80%
of patients with hepatic encephalopathy.182 The currently
known precipitating factors of hepatic encephalopathy
and the corresponding tests and treatments are shown in
Table 8.186
Page 14
14 The Korean Journal of Hepatology Vol. 18. No. 1, March 2012
Table 8. Precipitating factors, tests, and treatment of hepatic encephalopathy186
Precipitating factorTestsTreatment
Gastrointestinal bleedingEndoscopy, complete blood count, digital rectal
examination, stool blood test
Transfusion, bleeding treatment, vasoactive drugs
Infection Complete blood count, chest x-ray, urine analysis,
culture, diagnostic paracentesis
Broad-spectrum antibiotics
Constipation History taking, abdomen x-rayEnema or drug therapy
Protein intake History taking Limiting protein intake
DehydrationSkin elasticity, blood pressure, pulse rate, blood
urea nitrogen, creatinine
Stop diuretics or reduction, fluid therapy
Renal dysfunctionBlood urea nitrogen, creatinineStop diuretics or reduction, albumin, fluid therapy
HyponatremiaSerum sodium concentration Restriction water consumption, diuretics dose
adjustment or stop
Hypokalemia Serum potassium concentrationDiuretics dose adjustment or stop
Benzodiazepines History takingStop drug, flumazenil
Acute liver dysfunctionLiver function testConservative treatment
5-3-1. Medications
The primary treatment of hepatic encephalopathy is
nonabsorbable disaccharides such as lactulose (β-galactosido-
fructose) or lactitiol (β-galctoside sorbitol). These
treatments lead to the recovery of 70-90% of patients with
hepatic encephalopathy. Although nonabsorbable disaccha-
rides have been reported to have no significant effect on
hepatic encephalopathy,187 randomized controlled studies
have indicated a positive effect of lactulose in the treatment
and prevention of hepatic encephalopathy.188,189 Enema with
nonabsorbable disaccharides can be used until the cons-
ciousness is recovered. After consciousness is restored,
nonabsorbable disaccharides (15-45 mL, orally 2-4 times/day)
should be recommended for loose stool defecation 2-3 times
a day.
Antibiotics such as neomycin, metronidazole, and
rifaximin that are not absorbed by the intestine, affect
urea-producing bacteria and reduce the generation of
ammonia, thereby improving hepatic encephalopathy.
Neomycin and metronidazole are not recommended as
atreatment of hepatic encephalopathy because of their side
effects such as intestinal malabsorption, nephrotoxicity, and
ototoxicity for neomycin and peripheral neuropathy for
metronidazole.190 Rifaximin maintains high levels of
concentration in the intestine because it is not absorbed by
the intestine and remains in an active form until it is
excreted. It has a broad antimicrobial activity on aerobic and
anaerobic gram-positive and gram-negative bacteria. It has
been proven effective and safe in hepatic encephalopathy,191-193
and recently has been focused upon as a first-line treatment
for hepatic encephalopathy with a maximum dose of 1,200
Ornithine and aspartate are important substrates used to
metabolize ammonia to urea and glutamine. L-ornithine-
L-aspartate (LOLA) can therefore be administered to
patients with hepatic encephalopathy for reducing blood
ammonia levels, with subsequent improvements in hepatic
encephalopathy. LOLA is available in oral and injection
forms, both of which are available in Korea currently.
5-3-2. Liver transplantation
Liver transplantation is indicated in patients with severe
hepatic encephalopathy, who do not respond to the above
treatments. Patient with acute liver failure who shows hepatic
encephalopathy are also considered for liver transplantation
because of the poor prognosis.194
5-3-3. Prevention of relapse
Because the recurrence rate of hepatic encephalopathy is
50-70%,189,195,196 therapy for the prevention of recurrence
should be considered. Lactulose189 or rifaximin196 have been
used for the prevention of recurrence.
5-4. Minimal hepatic encephalopathy
5-4-1. Definition and diagnosis
Minimal hepatic encephalopathy is a mild form of hepatic
encephalopathy that is defined as a cognitive dysfunction
presenting a abnormal psychometric tests without clinical
Page 15
Ki Tae Suk, et al. Revision and update on clinical practice guideline for liver cirrhosis 15
1. What are the precipitating factors of hepatic
- Precipitating factors of hepatic encephalopathy are
gastrointestinal bleeding, infection, constipation, excessive
intake of protein, dehydration, renal function disorder,
electrolyte imbalance, psychoactive medication, and acute
hepatic injury. (A1)
2. How should hepatic encephalopathy be treated?
- Nonabsorbent disaccharides (ex. lactulose, lactitol) (A1)
and rifaximin (B1) are recommended for treating patients
with hepatic encephalopathy. Nonabsorbable disaccharides
can be used to adjust the bowel movement-loose stool
(2-3 times/day), and rifaximin 1,200 mg should be given
orally in 2-3 divided doses for 1-3 weeks.
- A lactulose enema is recommended in severe hepatic
encephalopathy (West Haven grade ≥III). (A1)
- LOLA can be used in patients with hepatic
encephalopathy, and LOLA of 20 g can be injected daily
for 1-2 weeks or LOLA of 6 g can be given orally 3 times
per day for 1-2 weeks. (B2)
- Flumazenil can be used in patients with hepatic
encephalopathy caused by benzodiazepine for the
improvement of consciousness. (B2)
- In patients who do not respond to treatment or acute liver
injury with hepatic encephalopathy, liver transplantation is
recommended. (A1)
- In patients with a history of hepatic encephalopathy,
nonabsorbable disaccharide can be used until patients have
loose stools 2-3 times a day (A1), or 600 mg of rifaximin
can be used twice a day (B1).
3. How protein be supplied to patients with hepatic encephal-
- Protein intake should be restricted in patients with initial
hepatic encephalopathy, and gradually can be increased
according to the patient's condition. (B1)
- Oral branched-chain amino acids can be used as a protein
source in case of worsening or recurrence of hepatic
encephalopathy due to as a consequence of high protein
intake. (B2)
4. Is it necessary to examine and treat minimal hepatic
encephalopathy for patients with LC?
- In patients with LC, if there are any symptoms of low
cognitive function, tests and treatment for minimal hepatic
encephalopathy can be considered. (B1)
symptoms.180 Overall, 22-74% of patients with non-fulminant
hepatic encephalopathy have minimal hepatic encephalo-
pathy,197 and its frequency is proportional to patient age and
severity of liver disease.197 It is impossible to diagnose
minimal hepatic encephalopathy on clinical examination
alone. Only mild disturbances in cognitive and psychomotor
functions can be observed. Patients with minimal hepatic
encephalopathy exhibit disability in most functional
behaviors such as social connection, alertness, emotional
behavior, sleep, work, and leisure.188,198
Mini-Mental State Examination can be useful in differen-
tiating West Haven criteria 0 and stage 1-2, and if the score is
23 or lower, it suggests that the patient has overt hepatic
encephalopathy causing a cognitive disorder and is not
a primary target for psychometric tests.199 Since there are
still no decisive diagnostic tests, psychometric hepatic
encephalopathy score battery is recommended as a standard
method consisting of number connection test-A, number
connection test-B, line drawing test, serial dotting test, and
digit symbol test, and its benefits have been proven in
studies from Spain, Germany, India, and Korea.181,200-202
5-4-2. Treatment
Cognition and health-related quality of life improve
significantly in the treatment group compared to placebo
group.188 It has been reported that microviral agents (e.g.,
probiotics, synbiotics, etc.) improve minimal encephalopathy
by changing intestinal normal flora and suppressing the
production of ammonia.203 Even though reports are
displayed that LOLA204 and acetyl L-carnitine205 improved
minimal encephalopathy, there is no evidence regarding its
This research was supported by a grant from the Ministry
of Health and Welfare, Republic of Korea (A102065) and
the Korean Association for the Study of the Liver (KASL).
The Korean version of this guideline is available on the
KASL web site (http://www.kasl.org/). This version is revision
and update of the clinical practice guideline established by
the Korean Association for the Study of the Liver (KASL) in
Conflict of interest
Authors attest that there are no commercial associations
that might be a conflict of interest in relation to the sub-
mitted manuscript.


text:
Gary Wilson made his first 147 break at the German Masters qualifiers in Barnsley tonight.
The world number 89 from Wallsend made the maximum in the fourth frame of his match against Ricky Walden, to make the score 2-2. He'll share the rolling prize of £2,500 with Dechawat Poomjaeng, who made a 147 yesterday, providing there are no more maximums tonight.
It's the 102nd official maximum in snooker history and third in five days following Poomjaeng's and one from Mark Selby at the williamhill.com UK Championship - also in a match against Walden.

subset: commoncrawl


text:
Rye, NY United States
Kaehler/moore Architects
Custom/More Than 3,500 Square Feet/ Merit
Designing for a rear lot can be tricky. Not only must the house relate to its immediate neighbors (positioned more prominently at streetside), but the approach is invariably lengthy. "The narrow street frontage and the long drive back from the street helped to produce a kind of forced progression and perspective," says architect Joeb Moore. "The tall, simple gable form lures the visitor's eye and provides a basic, childlike notion of what a house looks like."
The tall shingled house with its sweeping—and slightly exaggerated—rooflines and entry tower takes its cues from Victorian structures seen along the 300-foot approach. Here, though, many familiar forms are tweaked. Stainless steel outriggers sub for typical wooden brackets under the standing-seam lead-coated copper roof, and the chimney is topped with perforated stainless steel caps that appear translucent from some angles. The judges admired the ingenuity: "It's really inventive. It takes a familiar vocabulary and makes something different."
Inside, the plan responds elegantly to the narrow lot, with more formal areas in front and informal spaces in back. "There's a real economy of means," says Moore. "The house pulls you right up and reaches like a tree. It's a very simple solution to a client's program and the specifics of the site."
Please read our Content Guidelines before posting.
Philadelphia, Pennsylvania, United States
Studio of Metropolitan Design Architects
Edgartown, Massachusetts, United States
Patrick Ahearn Architect LLC
Phoenix, United States
hayes inc. architecture/interiors
New York, New York, United States
Derek Pirozzi Architecture Workshop LLC
Studio Sofield, design architect; SLCE Architects, architect of record


text:
- Homepage >
- News Archives >
- Article
Engineers work to better monitor missile health
May 13, 2013
By Heather R. Smith, Aviation and Missile Research, Development and Engineering Center Public Affairs
Story Highlights
- Army researchers are designing a sensor that only collects low frequency data and is capable of switching on and off, thus extending the battery's life.
Related Links
REDSTONE ARSENAL, Ala. (May 13, 2013) -- The U.S. Army Research, Development and Engineering Command's aviation and missile center is leveraging micro-electro-mechanical systems research in a new application to detect potentially damaging vibrations encountered by missiles during handling, transport and operation.
Stephen Marotta, Engineering Directorate project principal investigator, said MEMS research has been ongoing at Aviation and Missile Research, Development and Engineering Center for many years and many different applications have been successfully transitioned from the lab to the Soldier in the field.
In an effort to improve missile health monitoring, Marotta began collaborating with Mohan Sanghadasa, from AMRDEDC's Weapons Development and Integration Directorate, and Stephen Horowitz, an engineer with Ducommun Miltec.
The AMRDEC team is using technology, both current and in-development, to design a new MEMS sensor that will offer several benefits over current missile health monitoring systems.
"We've spent a number of years developing acoustic sensors, microphones based on piezoelectric materials," Horowitz said, "and there's not a huge difference between designing a microphone and designing a vibration sensor and accelerometers. It's a different structure, a different geometry, but we use the same fabrication processes to create them. On our first generation sensor, we used the same materials even."
One benefit of the new design is extended battery life.
Current missile health monitoring methods require a lot of power, because they collect vibration data at all frequencies. Research, however, has shown that the greatest risk for damage to missiles occurs during low vibration -- under 200 hertz. The AMRDEC team is designing a sensor that only collects low frequency data and is capable of switching on and off, thus extending the battery's life.
Marotta said the MEMS work meets the challenge set by AMRDEC director for missile development Steve Cornelius to get new capabilities into the hands of Soldiers, to leverage technology solutions that increase readiness, and to enable more affordable weapons.
"Applied research, led by the AMRDEC Engineering Directorate, is addressing those many challenges in an integrated fashion with other AMRDEC directorates, other RDECs, and other services to sustain its missile systems as efficiently and effectively as possible," Marotta said. "AMRDEC science and technology for monitoring of missile health or condition improves the accuracy of readiness reporting and reduces the overall missile sustainment burden. AMRDEC is making a positive impact with current technology transitions at present, as well as greatly benefiting future systems."
A prototype of the sensor should be complete later this year with transition into the field expected in 2014.
The team reported its research in a paper published by the Institute of Electrical and Electronics Engineers, "A Low Frequency MEMS Vibration Sensor for Low Power Missile Health Monitoring." The paper was nominated for best paper at the 2013 IEEE conference.
AMRDEC is part of the U.S. Army Research, Development and Engineering Command, which has the mission to develop technology and engineering solutions for America's Soldiers.
RDECOM is a major subordinate command of the U.S. Army Materiel Command. AMC is the Army's premier provider of materiel readiness -- technology, acquisition support, materiel development, logistics power projection, and sustainment -- to the total force, across the spectrum of joint military operations. If a Soldier shoots it, drives it, flies it, wears it, eats it or communicates with it, AMC provides it.


text:
- Narrow by:
- | Wheelchairs
- Home Health Care Equipment|
- Medical Equipment Rentals|
- Orthopedic Products|
- Used Medical Equipment
- See More
J & J Mobility is based in the city of Delaware and serves Central Ohio residents of Delaware, Fr... More >
Matching: Wheelchairs
ADT Medical Alert - Official Sales Center
Creative Mobility is about putting a positive spin on adaptive bicycles. Enabling people to go wh... More >
Matching: Wheelchairs
Matching: Wheelchairs
Matching: Wheelchairs
United Patient Care Inc
(937) 644-8554
702 Milford Ave, Marysville, OH | 43040 Map
United Patient Care is well known in the Marysville area and neighboring Union County communities... More >
Matching: Wheelchairs
You are currently searching Marysville Medical Equipment and Supplies: Wheelchairs Try other nearby locations.
Marion | Plain City | Richwood | North Lewisburg | Milford Center


text:
Upcoming Events
57 School Road Principal: Brian Bagley
Wilton, NH 03086 Assistant Principal: Susan Ballou
Telephone: (603) 654-6123 Fax: (603) 654-2104
Wilton, NH 03086 Assistant Principal: Susan Ballou
Telephone: (603) 654-6123 Fax: (603) 654-2104
The WLC WARRIORS BOOSTER CLUB is a new start-up organization which seeks to fill a need for our student athletes without impacting the school budget or tax rate. If you can donate time, have experience with non-profits, or are great with people, we need YOU!
If you would like to: Learn More About The Booster Club, Volunteer Your Time or Join the Board - Please contact Susan Bogdan 603-930-4636 or email: firstname.lastname@example.com
WLC Warriors Booster Club Mission
"The mission of the WLC Warriors Booster Club is to work toward the improvement and maintenance of the athletic facilities and programs at WLC Middle / High School.
It is the goal of the WLC Warriors Booster Club to provide for the maintenance of improvements made at WLC athletic facilities."
January 2015
Wilton-Lyndeborough Cooperative Middle School
Student of the Month
Wilton-Lyndeborough Cooperative Middle School
Student of the Month
Abby LeBlanc, Veronica Boyle, Sophia Sistachs, Paul VanBlarigan III, Harrison Kim, Owen McGettigan
To help support the class, click on the link below and order items online. Your purchases are shipped directly to your home and the class receives 40% profit on each and every sale. This promotion is good through July 1, 2015.
Exclusive Online Store-WLC MS/HS Class of 2016
If the link fails to take you to the shopping site, dont worry. Simply type in www.yankeecandlefundraising.com and enter group number 990003746 in the Start Shopping box. You can shop for the same Yankee Candle Fundraising items and your purchase will still benefit the class of 2016
Middle School Students
High School Students
Community Members
High School Students
Community Members
The FRES Elementary Building Project, is now the FRES Moving Project!
Volunteers are needed to assist the teachers packing, moving, unpacking, and arranging classroom and educational materials during the week before, during and after February Vacation. This is an excellent opportunity to visit your old elementary school, check out the new building AND on top of all that you can get COMMUNITY SERVICE hours !!!! Come by Guidance to sign up for all days and times or just a couple hours....you can also see Jenna
Bragdon !!!
Write about a time you were the leader in an important moment on the field or in your community. Describe what you did and what you learned from that experience. The essay needs to be written in 1,000 words or less.
Email your essay along with your name, college or university, year of graduation and contact information to email@example.com
Email your essay along with your name, college or university, year of graduation and contact information to email@example.com
All entries are due by July 1, 2015 -
The Childhood Cancer Lifeline launched a scholarship program for the 2014-2015 school year. The eligibility of this scholarship is specifically for childhood cancer survivors who are graduating from a New Hampshire High School. Additionally, students are eligible to receive a new laptop, if they have not received one from CCL as a result of a new diagnosis since January 1, 2013.
Graduates (or their families) can contact Suzanne Margarit, CCL program coordinator, at links@childhoodcancerlifeline.
Deadlines expire at midnight, EST (U.S.).
SAT Date | SAT Subject Tests Available (Find Dates) |
Registration Deadline | Late Registration Deadline |
Deadline for Changes |
Status | |
Phone/ Online |
May 2 |
Subject Tests |
Apr 6 |
Apr 17 |
Apr 21 |
Apr 21 |
Register Now |
Jun 6 |
Subject Tests |
May 8 |
May 22 |
May 27 |
May 27 |
Register Now |
Additional fees apply if you register late or make changes to your test type, center or date after registering.
- Regular Registration Fee: $52.50
- Late Registration Fee: $80.50
- Register online at http://sat.collegeboard.org/register
- SAT Question of the Day http://sat.collegeboard.org/practice/sat-question-of-the-day
- Customized SAT Study Plan http://sat.collegeboard.org/practice/sat-study-plan
- Practice Questions http://sat.collegeboard.org/practice/sat-practice-questions
- Full-Length Practice SAT http://sat.collegeboard.org/practice/sat-practice-test
- VLACS SAT Prep course at www.vlacs.org
2015-2016 Scheduling Process
This process has three phases:
Phase I Preliminary Course Selection Process
2015-2016 Preliminary Course Selection Packets were handed out on the following dates:
Wednesday, February 4th to those students entering grades 9 and 12 next year and on
Friday, February 6th to students entering grades 10 and 11 next year.
Students are in the process of choosing courses they would like to have run during the 2015-2016 school year. All Preliminary Course Selection paperwork will be handed in to Guidance on February 10th. This information will allow the 2015-2016 Master Schedule to be developed.
Phase II Course Selection Process
Once the Master Schedule is developed students will be presented with their Course Selection Packet and work with their Advisors during Advisory choosing courses for next year.
Phase III Arena Scheduling
On Friday, March 20th each student will attend ARENA scheduling; this process allows each student to build their own schedule.
The New Hampshire Department of Health and Human Services recently released information about the Ebola virus. Please follow this link if you are interested in learning more about this disease.
Enterovirus in Area
The City of Nashua Division of Public Health and Community Services recently sent information to our district about Enterovirus D-68 (EV-D68), a respiratory illness that can cause mild to severe cold and respiratory symptoms. As of September 10, 2014, a total of 84 people across six states have been confirmed cases of EV-D68. The towns of Wilton and Lyndeborough are in the area that needs to be aware of this community health concern. Please click on this link to learn more information.
Stop by the School Counseling Office to schedule
an appointment to complete the Common App !


text:
This is CRAZY, but my dishwasher will not CLOSE. HELP!
Apr 02, 2012 by alkapal in Cookware
Mystery Diner. 100% faked, i'll tell you why.
May 28, 2012 by puppeteer23 in Food Media & News
My Technivorm quit--service?
Oct 04, 2011 by splatgirl in Cookware
Pizza delivery charge
Mar 06, 2013 by rockandroller1 in Not About Food
Waitress at Elmwood Cafe Berkeley makes racist assumption
Feb 01, 2015 by karenfinan in San Francisco Bay Area
What are your thoughts on the city's coffee offerings?
Sep 04, 2014 by FeeFee34 in San Francisco Bay Area
KFC Crosses the Line
Jan 26, 2015 by ferret in Chains
Faculty candidate Interview dinner choices
Jan 07, 2015 by professorMOMO in San Diego
Anyone else getting tired of "new" Craft Beer,Gourmet Burgers & 3rd Wave Coffee joints in Bay Area?
Dec 16, 2014 by Mission in San Francisco Bay Area
Anyone else over Guy Fierri?
Jan 16, 2015 by Houcasey in Food Media & News
Diners, Drive-ins, Dives, and Disgusting
Jun 23, 2008 by TonyO in Food Media & News
Glass Stove Top put in/ and I do nothing but burn everythiing on it
Feb 06, 2011 by somethingnotburnt in Cookware
Favorable review of new Olive Garden in Grand Forks, ND
Mar 08, 2012 by GilbyEast in Food Media & News
All I want is a good cup of coffee at home. [moved from General Topics]
Nov 17, 2011 by mikey031 in Cookware
Descaling solution for espresso machines (and coffee makers)
Jan 16, 2007 by NYChristopher in Cookware
Pinhole Coffee (Bernal Heights, San Francisco)
Dec 08, 2014 by Melanie Wong in San Francisco Bay Area
May I vent? (living with a reasonably Chowish person who isn't quite a Chowhound..)
Dec 28, 2014 by janetofreno in Not About Food
Bourdain vs. Deen
Aug 19, 2011 by alliegator in Food Media & News
Endangered and Extinct: Taco Flavored Doritos
Sep 13, 2000 by Jason Perlow in General Topics
Questions about Nespresso machines and Frothers
Nov 11, 2012 by Breadcrumbs in Cookware
Food mythbusters . What's your belief or not ?
Oct 03, 2014 by emglow101 in General Topics
Pennsylvania Dutch Egg Nog
Dec 12, 2013 by CarrieWas218 in San Francisco Bay Area
Serious Bosch Issue - Design problem?
Dec 23, 2014 by chicgail in Cookware
Wrecking Ball Coffee (Cow Hollow, San Francisco)
Sep 05, 2014 by Melanie Wong in San Francisco Bay Area
Starbucks may have brought out the heavy artillery
Dec 04, 2014 by poser in Greater Seattle
People Reading Me


text:
Advanced Search
Project Cargo Bi-Annual
Georgia Ports
View Issue #595 Now!
Your Email:
Your Name:
Message: Seaboard Foods to add 45 natural gas-powered Kenworth Trucks to move hogs and biodiesel Canada's new transport minister, Lisa Raitt, will become the government's point person on railway regulation, a highly sensitive task in the aftermath of the train derailment earlier this month that devastated a small town and left 50 people dead. Read Full Article: http://www.ajot.com/news/seaboard-foods-to-add-45-natural-gas-powered-kenworth-trucks-to-move-hogs-a


text:
TECUMSEH - The tight-knit neighbourhood that watched a kid who loved to play road hockey grow into a talented Windsor Spitfires captain was reeling Monday following the sudden death of 19-year-old Mickey Renaud.
Residents of quiet Michael Drive in Tecumseh, where the Renaud family has lived since the early 1990s, were shocked to learn that Renaud collapsed at home Monday and died after being rushed to hospital without vital signs.
"He was in his prime," said Brad Hedderson, whose children grew up with Renaud and his older brother Remy, playing road hockey and hanging out. "He was a fantastic athlete and a good, solid kid."
Renaud lived in a tidy, brick home on Michael Drive with his parents, Jane and Mark Renaud, a former National Hockey League player, and siblings Remy and Penny, who neighbours said were 21 and six, respectively.
Hedderson and his wife Tish said they couldn't understand how a young, six-foot-three, 230-pound man who appeared to be in great shape, could die so suddenly.
"It's an absolute shock," Tish said.
Blinking back tears, Hedderson remembered referring to Renaud as "Rocket" because of his speed and agility on ice and on the street while playing road hockey with other kids in the neighbourhood.
Hedderson said Renaud's talent was obvious at a young age, even before there was any indication he had a lustrous hockey career ahead of him.
"I used to tease him.... I thought I'd start calling him Rocket and maybe it would stick when he became famous," he said with a laugh.
Hedderson said he was so proud of Renaud when he was drafted by the Windsor Spitfires in 2004, he got a Spits jersey with Renaud's name. Signed by Renaud, the jersey is now invaluable to the Heddersons.
Their daughter, St. Anne basketball star Brittany Hedderson, celebrated at the 2007 WESPY awards with Renaud last September when both athletes won awards for their achievements.
"She's taking this hard," Tish said.
Across the street, the Robinson family listened to radio newscasts about Renaud's death in disbelief, remembering a "very respectful, polite boy" who didn't let the Spits fame go to his head.
"He was a Windsor Spitfire, but also very much a Tecumseh boy," said an emotional Linda Robinson, whose family is close with the Renauds. Robinson and her husband Derek remembered how the two families met more than 15 years ago, when they moved into the same neighbourhood and bonded over their children and common interests.
When Renaud was chosen by the Calgary Flames in the fifth round of the NHL draft last year, the whole neighbourhood was elated, Robinson said.
Still, Renaud was always "just Mickey" to those who knew him before his success made headlines, she said.
Robinson's son Scott was one of the friends comforting Remy Renaud Monday afternoon. Several young men hugged in front of the Renaud home and went inside. One of them asked reporters not to bother the family.
Robinson's older daughter Heather, 19, who went to school with Renaud since junior kindergarten through their years at St. Anne high school, said their friendship was always solid, no matter how busy Renaud's schedule was.
"Even if we lost touch for three months, he was always there for me. We never stopped talking," she said.
For Heather's 12-year-old sister Jillian, Renaud was "like a big brother."
"Look at the legacy he left, at just 19," Linda Robinson said through tears. "Not a lot of kids can say that ... that they've done so much in such a short time.
"This is a huge tragedy for the community, for the whole city."
By Monday evening, several online groups dedicated to Renaud appeared on the popular social networking website Facebook. People from across Windsor and Essex County, including many young Spits fans, posted their condolences and shared memories and pictures of Renaud.


text:
In the wake of dry spell in the region, more calls are expected
With dry spell continuing in the region, Fire and Rescue Services department personnel are on an alert ahead of Deepavali.
According to officials, in the past, prior to the D-day, when there was good amount of rain, the number of calls received by the fire brigade was relatively low. With dry spell reported in many of the southern districts, the calls are expected to be higher this season.
The southern region of Fire and Rescue Services comprises Madurai City, Madurai, Theni, Ramanathapuram, Sivaganga, Virudunagar, Kanyakumari, Tuticorin and Tirunelveli districts. The authorities here want to ensure that all vulnerable locations and points are taken care of.
In the last fortnight, the fire officers in the respective fire stations had been campaigning on the need to burst crackers safely, through schools, local electronic media and other agencies, said Deputy Director (Fire and Rescue Services) M. Shahul Hameed on Monday.
The campaign in schools involving social workers and non-governmental organisations had fetched some results in the past. Rallies and live demonstration and mock drills were held to take the message to the general public. There had been a lot of awareness which had resulted in people taking precautions while bursting crackers.
Children should burst crackers only under the supervision of elders and cotton outfit was advisable while bursting crackers. Similarly, under no circumstances aerial fireworks should be burst near thatched roofs or petrol pumps, but only in open spaces. In the event of burns, by pouring cold water, the degree of intensity of injury could be reduced to a great extent. These were some of the tips shared by them at the campaign.
Fire calls data
The fire calls are analysed in the following pattern — one day ahead of Deepavali, on the festival day and post-Deepavali day, officials said.
The data available with the Fire and Rescue Services department shows that except in 2009 (in the last six years), the number of calls received were well within the manageable limits in the southern region. In 2006 - 18 calls; 2007 - 32; 2008 – 54; 2009 – 151; 2010 - 28 and 2011- 11 calls.
In Madurai city, the fire calls on Deepavali day in the last six years were: 2006 – 4; 2007 – 11; 2008 – 23; 2009 – 31; 2010 – 5; and 2011- 4 calls.
Mr. Shahul Hameed told The Hindu that they are fully geared to handle any emergencies. All fire officers were on alert with fire tenders positioned at vantage points.


text:
Prolaris(R) Test Predicts Mortality Risk In Prostate Cancer Biopsy Study
SALT LAKE CITY, May 20, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today presented new data from a clinical validation study of Prolaris at the 2014 American Urological Association (AUA) Annual Meeting in Orlando, Fla. The study is the largest validation study to date of any gene-based prognostic test in patients with prostate cancer who were diagnosed by needle biopsy. A key finding was that the Prolaris test accurately differentiated newly diagnosed patients who were likely to die from prostate cancer within 10 years from those with lower-risk disease, which should open the door to more appropriate clinical care for patients at all risk levels. Prolaris is a novel molecular diagnostic test that accurately predicts cancer-specific death and metastases in men with prostate cancer and is a much stronger indicator of clinical outcomes than Gleason score or PSA.
"The aggressiveness of newly diagnosed prostate cancer is variable and difficult to predict. What clinicians really need is a well-validated prognostic test that accurately predicts disease-specific mortality and can improve patient care," said Jack Cuzick, PhD., study investigator and head of the Centre for Cancer Prevention at Queen Mary University of London. "Currently, with standard clinical tools like Gleason Score or PSA, we can't adequately define prognosis. The Prolaris test provides useful new information and is highly prognostic for disease-specific death among men being conservatively treated."
In this study, the goal was to validate the Prolaris test score in 761 conservatively managed prostate cancer patients diagnosed by needle biopsy. The primary endpoint was prostate cancer death and the median follow-up time was 9.5 years. The results showed that for each one unit increase in the Prolaris score, patients had approximately double the risk of dying from prostate cancer (see table).
Prolaris Predicts 10-Year Death Rates from Prostate Cancer | ||||
Prolaris Test Score | <0 | 0-1 | 1.1-2 | >2 |
Death Rate (%) | 7 | 15 | 36 | 59 |
Check Out Our Best Services for Investors
Action Alerts PLUS
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Quant Ratings
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Product Features:
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Stocks Under $10
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Check Out Our Best Services for Investors
Dividend Stock Advisor
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Product Features:
- Model Portfolio
- Intra Day Trade alerts
- Access to Quant Ratings
Options Profits
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- Actionable options commentary and news
- Real-time trading community